Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions

References

• Gatto CL, Broadie K. Drosophila modeling of heritable neurodevelopmental disorders. Curr Opin Neurobiol 2011;21(6):834-41
   Google Scholar
• Gomez-Mancilla B, Berry-Kravis E, Hagerman R, et al. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 2014;23(1):125-34
   PubMed Web of Science ®Google Scholar
• Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol 2014;10(2):74-81
   PubMed Web of Science ®Google Scholar
• Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr 2010;31(7):564-81
   PubMed Web of Science ®Google Scholar
• Neurofibromatosis. Conference statement. National institutes of health consensus development conference. Arch Neurol 1988;45(5):575-8
   PubMedGoogle Scholar
• Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991;11(4):931-40
   Google Scholar
• Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991;88(21):9658-62
   Google Scholar
• Abernathy CR, Rasmussen SA, Stalker HJ, et al. NF1 mutation analysis using a combined heteroduplex/SSCP approach. Hum Mutat 1997;9(6):548-54
   Google Scholar
• Cnossen MH, van der Est MN, Breuning MH, et al. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? Hum Mutat 1997;9(5):458-64
   Google Scholar
• Kayes LM, Burke W, Riccardi VM, et al. Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet 1994;54(3):424-36
   Google Scholar
• Leppig KA, Kaplan P, Viskochil D, et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 1997;73(2):197-204
   Google Scholar
• Tonsgard JH, Yelavarthi KK, Cushner S, et al. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997;73(1):80-6
   Google Scholar
• Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 2002;17(8):562-70; discussion 571-562, 646-551
   Google Scholar
• Wu BL, Austin MA, Schneider GH, et al. Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. Am J Med Genet 1995;59(4):528-35
   Google Scholar
• Wu BL, Schneider GH, Korf BR. Deletion of the entire NF1 gene causing distinct manifestations in a family. Am J Med Genet 1997;69(1):98-101
   Google Scholar
• Kehrer-Sawatzki H, Vogt J, Mussotter T, et al. Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions. Neurogenetics 2012;13(3):229-36
   PubMedGoogle Scholar
• Pasmant E, Sabbagh A, Spurlock G, et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 2010;31(6):E1506-18
   PubMed Web of Science ®Google Scholar
• Upadhyaya M, Huson SM, Davies M, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007;80(1):140-51
   PubMed Web of Science ®Google Scholar
• Ars E, Kruyer H, Morell M, et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet 2003;40(6):e82
   Google Scholar
• Sharif S, Upadhyaya M, Ferner R, et al. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 2011;48(4):256-60
   PubMedGoogle Scholar
• Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993;53(2):305-13
   PubMed Web of Science ®Google Scholar
• Palmer C, Szudek J, Joe H, et al. Analysis of neurofibromatosis 1 (NF1) lesions by body segment. Am J Med Genet A 2004;125A(2):157-61
   Google Scholar
• Szudek J, Birch P, Riccardi VM, et al. Associations of clinical features in neurofibromatosis 1 (NF1). Genet Epidemiol 2000;19(4):429-39
   Google Scholar
• Gutmann DH. Eliminating barriers to personalized medicine: Learning from neurofibromatosis type 1. Neurology 2014;83(5):463-71
   Google Scholar
• Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol 2013;55(2):111-25
   PubMed Web of Science ®Google Scholar
• North K, Gutmann DH. International Child Neurology Association. Neurofibromatosis type 1 in childhood. Mac Keith Press, for the International Child Neurology Association; London, England: 1997
   Google Scholar
• Ferner RE, Hughes RA, Weinman J. Intellectual impairment in neurofibromatosis 1. J Neurol Sci 1996;138(1-2):125-33
   PubMed Web of Science ®Google Scholar
• Hofman KJ, Harris EL, Bryan RN, Denckla MB. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994;124(4):S1-8
   PubMed Web of Science ®Google Scholar
• Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005;65(7):1037-44
   PubMed Web of Science ®Google Scholar
• Mazzocco M TJ, Denckla M, Hofman K, et al. Language and reading deficits associated with neurofibromatosis type 1: evidence for a not-so-nonverbal learning disability. Dev Neuropsychol 1995;11:19
   Google Scholar
• Krab LC, Aarsen FK, de Goede-Bolder A, et al. Impact of neurofibromatosis type 1 on school performance. J Child Neurol 2008;23(9):1002-10
   PubMedGoogle Scholar
• Eliason MJ. Neurofibromatosis: implications for learning and behavior. J Dev Behav Pediatr 1986;7(3):175-9
   PubMed Web of Science ®Google Scholar
• Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet 1989;26(11):712-21
   Google Scholar
• Varnhagen CK, Lewin S, Das JP, et al. Neurofibromatosis and psychological processes. J Dev Behav Pediatr 1988;9(5):257-65
   Google Scholar
• Cutting LE, Clements AM, Lightman AD, et al. Cognitive profile of neurofibromatosis type 1: rethinking nonverbal learning disabilities. Learn Disabil Res Pract 2004;19:10
   Google Scholar
• Hachon C, Iannuzzi S, Chaix Y. Behavioural and cognitive phenotypes in children with neurofibromatosis type 1 (NF1): the link with the neurobiological level. Brain Dev 2011;33(1):52-61
   Google Scholar
• Kayl AE, Moore BD 3rd. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 2000;6(2):117-24
   Google Scholar
• Levine TM, Materek A, Abel J, et al. Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 2006;13(1):8-20
   PubMedGoogle Scholar
• Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 1999;89(1):45-52
   PubMed Web of Science ®Google Scholar
• Pride N, Payne JM, Webster R, et al. Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 2010;25(7):834-41
   PubMed Web of Science ®Google Scholar
• Roy A, Roulin JL, Charbonnier V, et al. Executive dysfunction in children with neurofibromatosis type 1: a study of action planning. J Int Neuropsychol Soc 2010;16(6):1056-63
   PubMed Web of Science ®Google Scholar
• Descheemaeker MJ, Ghesquiere P, Symons H, et al. Behavioural, academic and neuropsychological profile of normally gifted Neurofibromatosis type 1 children. J Intellect Disabil Res 2005;49(Pt 1):33-46
   Google Scholar
• Shilyansky C, Karlsgodt KH, Cummings DM, et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci USA 2010;107(29):13141-6
   Google Scholar
• North K, Joy P, Yuille D, et al. Cognitive function and academic performance in children with neurofibromatosis type 1. Dev Med Child Neurol 1995;37(5):427-36
   Google Scholar
• Payne JM, Hyman SL, Shores EA, North KN. Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. Child Neuropsychol 2011;17(4):313-29
   PubMed Web of Science ®Google Scholar
• Isenberg JC, Templer A, Gao F, et al. Attention skills in children with neurofibromatosis type 1. J Child Neurol 2013;28(1):45-9
   Google Scholar
• Clements-Stephens AM, Rimrodt SL, Gaur P, Cutting LE. Visuospatial processing in children with neurofibromatosis type 1. Neuropsychologia 2008;46(2):690-7
   PubMedGoogle Scholar
• Coude FX, Mignot C, Lyonnet S, Munnich A. Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children. Behav Genet 2006;36(5):660-4
   Google Scholar
• Cutting LE, Levine TM. Cognitive profile of children with neurofibromatosis and reading disabilities. Child Neuropsychol 2010;16(5):417-32
   PubMed Web of Science ®Google Scholar
• Eldridge R, Denckla MB, Bien E, et al. Neurofibromatosis type 1 (Recklinghausen’s disease). Neurologic and cognitive assessment with sibling controls. Am J Dis Child 1989;143(7):833-7
   Google Scholar
• Koth CW, Cutting LE, Denckla MB. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 2000;6(3):185-94
   PubMed Web of Science ®Google Scholar
• Mautner VF, Kluwe L, Thakker SD, Leark RA. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002;44(3):164-70
   PubMed Web of Science ®Google Scholar
• Ullrich NJ, Ayr L, Leaffer E, et al. Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol 2010;25(10):1195-202
   Google Scholar
• Watt SE, Shores A, North KN. An examination of lexical and sublexical reading skills in children with neurofibromatosis type 1. Child Neuropsychol 2008;14(5):401-18
   PubMed Web of Science ®Google Scholar
• Gilboa Y, Rosenblum S, Fattal-Valevski A, et al. Using a Virtual Classroom environment to describe the attention deficits profile of children with Neurofibromatosis type 1. Res Dev Disabil 2011;32(6):2608-13
   PubMed Web of Science ®Google Scholar
• Batista PB, Lemos SM, Rodrigues LO, de Rezende NA. Auditory temporal processing deficits and language disorders in patients with neurofibromatosis type 1. J Commun Disord 2014;48:18-26
   Google Scholar
• Bawden H, Dooley J, Buckley D, et al. MRI and nonverbal cognitive deficits in children with neurofibromatosis 1. J Clin Exp Neuropsychol 1996;18(6):784-92
   PubMed Web of Science ®Google Scholar
• Huijbregts S, Swaab H, de Sonneville L. Cognitive and motor control in neurofibromatosis type I: influence of maturation and hyperactivity-inattention. Dev Neuropsychol 2010;35(6):737-51
   PubMed Web of Science ®Google Scholar
• Brown JA, Emnett RJ, White CR, et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet 2010;19(22):4515-28
   PubMed Web of Science ®Google Scholar
• Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002;415(6871):526-30
   PubMed Web of Science ®Google Scholar
• Costa RM, Yang T, Huynh DP, et al. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet 2001;27(4):399-405
   Google Scholar
• Cui Y, Costa RM, Murphy GG, et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008;135(3):549-60
   PubMed Web of Science ®Google Scholar
• Silva AJ, Frankland PW, Marowitz Z, et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 1997;15(3):281-4
   PubMedGoogle Scholar
• Cutting LE, Koth CW, Denckla MB. How children with neurofibromatosis type 1 differ from “typical” learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000;17(1):29-47
   PubMed Web of Science ®Google Scholar
• Dilts CV, Carey JC, Kircher JC, et al. Children and adolescents with neurofibromatosis 1: a behavioral phenotype. J Dev Behav Pediatr 1996;17(4):229-39
   PubMed Web of Science ®Google Scholar
• Erdogan-Bakar E, Cinbis M, Ozyurek H, et al. Cognitive functions in neurofibromatosis type 1 patients and unaffected siblings. Turk J Pediatr 2009;51(6):565-71
   Google Scholar
• Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 2006;48(12):973-7
   PubMed Web of Science ®Google Scholar
• Moore BD 3rd, Slopis JM, Jackson EF, et al. Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 2000;54(4):914-20
   Google Scholar
• Schrimsher GW, Billingsley RL, Slopis JM, Moore BD 3rd. Visual-spatial performance deficits in children with neurofibromatosis type-1. Am J Med Genet A 2003;120A(3):326-30
   Google Scholar
• Violante IR, Ribeiro MJ, Cunha G, et al. Abnormal brain activation in neurofibromatosis type 1: a link between visual processing and the default mode network. PLoS One 2012;7(6):e38785
   Google Scholar
• Ribeiro MJ, d’Almeida OC, Ramos F, et al. Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits. J Neurodev Disord 2014;6(1):4
   Google Scholar
• Barton B, North K. Social skills of children with neurofibromatosis type 1. Dev Med Child Neurol 2004;46(8):553-63
   PubMed Web of Science ®Google Scholar
• Johnson NS, Saal HM, Lovell AM, Schorry EK. Social and emotional problems in children with neurofibromatosis type 1: evidence and proposed interventions. J Pediatr 1999;134(6):767-72
   PubMed Web of Science ®Google Scholar
• Noll RB, Reiter-Purtill J, Moore BD, et al. Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A 2007;143(19):2261-73
   Google Scholar
• Huijbregts SC, de Sonneville LM. Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1? Behav Genet 2011;41(3):430-6
   Google Scholar
• Johnson H, Wiggs L, Stores G, Huson SM. Psychological disturbance and sleep disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2005;47(4):237-42
   PubMed Web of Science ®Google Scholar
• Garg S, Green J, Leadbitter K, et al. Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics 2013;132(6):e1642-8
   PubMed Web of Science ®Google Scholar
• Walsh KS, Velez JI, Kardel PG, et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 2013;55(2):131-8
   Google Scholar
• Gaffney GR, Tsai LY. Magnetic resonance imaging of high level autism. J Autism Dev Disord 1987;17(3):433-8
   Google Scholar
• Gillberg C, Forsell C. Childhood psychosis and neurofibromatosis--more than a coincidence? J Autism Dev Disord 1984;14(1):1-8
   Google Scholar
• Mouridsen SE, Andersen LB, Sorensen SA, et al. Neurofibromatosis in infantile autism and other types of childhood psychoses. Acta Paedopsychiatr 1992;55(1):15-18
   Google Scholar
• Szatmari P, Bremner R, Nagy J. Asperger’s syndrome: a review of clinical features. Can J Psychiatry 1989;34(6):554-60
   PubMed Web of Science ®Google Scholar
• Williams PG, Hersh JH. Brief report: the association of neurofibromatosis type 1 and autism. J Autism Dev Disord 1998;28(6):567-71
   Google Scholar
• Adviento B, Corbin IL, Widjaja F, et al. Autism traits in the RASopathies. J Med Genet 2014;51(1):10-20
   Google Scholar
• Berg JM, Geschwind DH. Autism genetics: searching for specificity and convergence. Genome Biol 2012;13(7):s
   Google Scholar
• Lorenzo J, Barton B, Acosta MT, North K. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr 2011;158(4):660-5
   PubMed Web of Science ®Google Scholar
• Billingsley RL, Jackson EF, Slopis JM, et al. Functional magnetic resonance imaging of phonologic processing in neurofibromatosis 1. J Child Neurol 2003;18(11):731-40
   Google Scholar
• Billingsley RL, Jackson EF, Slopis JM, et al. Functional MRI of visual-spatial processing in neurofibromatosis, type I. Neuropsychologia 2004;42(3):395-404
   Google Scholar
• Brown JA, Diggs-Andrews KA, Gianino SM, Gutmann DH. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Mol Cell Neurosci 2012;49(1):13-22
   Google Scholar
• Brown JA, Gianino SM, Gutmann DH. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci 2010;30(16):5579-89
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003;23(26):8949-54
   PubMed Web of Science ®Google Scholar
• Guo HF, The I, Hannan F, et al. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 1997;276(5313):795-8
   Google Scholar
• Guo HF, Tong J, Hannan F, et al. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 2000;403(6772):895-8
   PubMed Web of Science ®Google Scholar
• Hegedus B, Dasgupta B, Shin JE, et al. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell stem cell 2007;1(4):443-57
   Google Scholar
• The I, Hannigan GE, Cowley GS, et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 1997;276(5313):791-s
   Google Scholar
• Tong J, Hannan F, Zhu Y, et al. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 2002;5(2):95-6
   Google Scholar
• Hannan F, Ho I, Tong JJ, et al. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hum Mol Genet 2006;15(7):1087-98
   Google Scholar
• Hegedus B, Yeh TH, Lee da Y, et al. Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet 2008;17(19):2956-66
   Google Scholar
• Andersen LB, Ballester R, Marchuk DA, et al. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol 1993;13(1):487-95
   PubMedGoogle Scholar
• Bernards A, Haase VH, Murthy AE, et al. Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and absence of expression in a neuroblastoma line. DNA Cell Biol 1992;11(10):727-34
   Google Scholar
• Danglot G, Regnier V, Fauvet D, et al. Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5’ part of the gene. Hum Mol Genet 1995;4(5):915-20
   Google Scholar
• Danglot G, Teinturier C, Duverger A, Bernheim A. Tissue-specific alternative splicing of neurofibromatosis 1 (NF1) mRNA. Biomed Pharmacother 1994;48(8-9):365-72
   Google Scholar
• Geist RT, Gutmann DH. Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci Lett 1996;211(2):85-8
   Google Scholar
• Gutman DH, Andersen LB, Cole JL, et al. An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. Hum Mol Genet 1993;2(7):989-92
   Google Scholar
• Gutmann DH, Cole JL, Collins FS. Expression of the neurofibromatosis type 1 (NF1) gene during mouse embryonic development. Prog Brain Res 1995;105:327-35
   PubMedGoogle Scholar
• Gutmann DH, Geist RT, Rose K, Wright DE. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev Dyn 1995;202(3):302-11
   Google Scholar
• Gutmann DH, Geist RT, Wright DE, Snider WD. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ 1995;6(3):315-23
   Google Scholar
• Gutmann DH, Zhang Y, Hirbe A. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann Neurol 1999;46(5):777-82
   Google Scholar
• Huynh DP, Nechiporuk T, Pulst SM. Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development. Dev Biol 1994;161(2):538-51
   Google Scholar
• Mantani A, Wakasugi S, Yokota Y, et al. A novel isoform of the neurofibromatosis type-1 mRNA and a switch of isoforms during murine cell differentiation and proliferation. Gene 1994;148(2):245-51
   Google Scholar
• Suzuki Y, Suzuki H, Kayama T, et al. Brain tumors predominantly express the neurofibromatosis type 1 gene transcripts containing the 63 base insert in the region coding for GTPase activating protein-related domain. Biochem Biophys Res Commun 1991;181(3):955-61
   Google Scholar
• Metheny LJ, Skuse GR. NF1 mRNA isoform expression in PC12 cells: modulation by extrinsic factors. Exp Cell Res 1996;228(1):44-9
   Google Scholar
• Buchanan ME, Davis RL. A distinct set of Drosophila brain neurons required for neurofibromatosis type 1-dependent learning and memory. J Neurosci 2010;30(30):10135-43
   Google Scholar
• Brown JA, Xu J, Diggs-Andrews KA, et al. PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp Neurol 2011;232(2):333-8
   Google Scholar
• Hsueh YP. From neurodevelopment to neurodegeneration: the interaction of neurofibromin and valosin-containing protein/p97 in regulation of dendritic spine formation. J Biomed Sci 2012;19:33
   Google Scholar
• Lin YL, Lei YT, Hong CJ, Hsueh YP. Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway. J Cell Biol 2007;177(5):829-41
   Google Scholar
• Guilding C, McNair K, Stone TW, Morris BJ. Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB. Eur J Neurosci 2007;25(1):99-105
   Google Scholar
• Ho IS, Hannan F, Guo HF, et al. Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation. J Neurosci 2007;27(25):6852-7
   Google Scholar
• Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005;15(21):1961-7
   PubMed Web of Science ®Google Scholar
• Mainberger F, Jung NH, Zenker M, et al. Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1. BMC Neurol 2013;13:131
   PubMedGoogle Scholar
• Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008;300(3):287-94
   Google Scholar
• van der Vaart T, Plasschaert E, Rietman AB, et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol 2013;12(11):1076-83
   PubMed Web of Science ®Google Scholar
• Holstein DH, Vollenweider FX, Geyer MA, et al. Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiat Res 2013;205(1-2):117-26
   Google Scholar
• Diggs-Andrews KA, Tokuda K, Izumi Y, et al. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol 2013;73(2):309-15
   PubMed Web of Science ®Google Scholar
• Diggs-Andrews KA, Brown JA, Gianino SM, et al. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol 2014;75(2):309-16
   PubMedGoogle Scholar
• Chabernaud C, Mennes M, Kardel PG, et al. Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1. Neurosci Lett 2012;515(1):28-33
   Google Scholar
• Pasca SP, Portmann T, Voineagu I, et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011;17(12):1657-62
   PubMed Web of Science ®Google Scholar
• Rauen KA, Banerjee A, Bishop WR, et al. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 2011;157C(2):136-46
   PubMed Web of Science ®Google Scholar
• Neurofibromatosis Type 1 patient registry. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01410006&Search=Search
   Google Scholar
• Modifying genes in neurofibromatosis 1. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01650142&Search=Search
   Google Scholar
• Quality of friendships in children with neurofibromatosis. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00508235&Search=Search
   Google Scholar
• How neurofibromatosis Type 1 (NF1) affects schoolwork and self-esteem. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01626846&Search=Search
   Google Scholar
• Adaptation and quality of life among adults with neurofibromatosis type I. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00684398&Search=Search
   Google Scholar
• Neuropsychological impairment and quality of life in neurofibromatosis type 1. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01851135&Search=Search
   Google Scholar
• Neurobiology and treatment of reading disability in NF-1. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00624234&Search=Search
   Google Scholar
• NF1-Attention: study of children with neurofibromatosis type 1 treated by methylphenidate. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00169611&Search=Search
   Google Scholar
• Trial to evaluate the safety of lovastatin in individuals with neurofibromatosis type I (NF1). Available from: www.clinicaltrials.gov/ct2/results?term=NCT00352599&Search=Search
   Google Scholar
• A randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00853580&Search=Search
   Google Scholar